Converge Bio
-20%
est. 2Y upside i
Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.
Rank
#2759
Sector
Biotech
Est. Liquidity
~5Y
Data Quality
Data: LowConverge Bio is a high-risk, early-stage AI biotech.
Last updated: July 3, 2026
If Converge Bio secures major pharma partnerships or achieves breakthrough in platform, valuation could double to $200M in 2 years.
With no near-term revenue and high cash burn, valuation likely declines 20% due to dilution and lack of milestones.
If competition from Isomorphic Labs intensifies or funding dries up, common stock could be nearly worthless after preference liquidation.
Preference Stack Risk
moderateFunding Intensity
33%Total funding $33M, assumed valuation $100M, preference overhang is 33%.
Dilution Risk
highSeries A company will likely raise more capital, diluting common stock by 20-30%.
Secondary Liquidity
noneNo secondary market activity reported.
Questions to Ask at the Interview
Strategic questions based on Converge Bio's data — designed to show you've done your homework.
- 1
“How does Converge Bio's platform differentiate from Isomorphic Labs?”
- 2
“What is the expected timeline to first revenue milestone?”
- 3
“What is the company's runway and expected next funding round?”
Community
Valuation Sentiment
Our model estimates -20% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.